MedTrace Logo

Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects

NCT00544934 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2016-02-10

No results posted yet for this study

Summary

A dose-ranging study evaluating safety, metabolism and therapeutic dosing of three multiple dose levels of GLY-230 in healthy and diabetic subjects

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

GLY-230

125, 250 0r 375 mg bid for 14 days

OTHER

Placebo

No drug administered

Sponsors & Collaborators

  • Glycadia

    lead INDUSTRY

Principal Investigators

  • Laurence Kennedy, M.D. · University of Florida

  • Maria del Pilar Solano, M.D. · University of Miami, Miami, Florida

  • Lis Cohen, D.O. · Suncoast Clinical Research, New Port Richey, Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Completion
2007-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544934 on ClinicalTrials.gov